NZ331978A - Monoclonal antibody to CEA (carcinomembryonic antigen), conjugates comprising said antibody, and their therapeutic use in an adept system - Google Patents
Monoclonal antibody to CEA (carcinomembryonic antigen), conjugates comprising said antibody, and their therapeutic use in an adept systemInfo
- Publication number
- NZ331978A NZ331978A NZ331978A NZ33197897A NZ331978A NZ 331978 A NZ331978 A NZ 331978A NZ 331978 A NZ331978 A NZ 331978A NZ 33197897 A NZ33197897 A NZ 33197897A NZ 331978 A NZ331978 A NZ 331978A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibody
- seq
- conjugate
- carcinomembryonic
- cea
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9609405.7A GB9609405D0 (en) | 1996-05-04 | 1996-05-04 | Protein |
| GBGB9703103.3A GB9703103D0 (en) | 1997-02-14 | 1997-02-14 | Protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ331978A true NZ331978A (en) | 2000-05-26 |
Family
ID=26309272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ331978A NZ331978A (en) | 1996-05-04 | 1997-04-29 | Monoclonal antibody to CEA (carcinomembryonic antigen), conjugates comprising said antibody, and their therapeutic use in an adept system |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US6277599B1 (enExample) |
| EP (1) | EP0896626B1 (enExample) |
| JP (1) | JP2000510692A (enExample) |
| CN (1) | CN1217750A (enExample) |
| AT (1) | ATE350478T1 (enExample) |
| AU (1) | AU719513B2 (enExample) |
| BR (1) | BR9708910A (enExample) |
| CA (1) | CA2250579A1 (enExample) |
| CZ (1) | CZ353698A3 (enExample) |
| DE (1) | DE69737188T2 (enExample) |
| ES (1) | ES2279539T3 (enExample) |
| HU (1) | HUP9901562A3 (enExample) |
| IL (1) | IL126772A0 (enExample) |
| NO (1) | NO985120L (enExample) |
| NZ (1) | NZ331978A (enExample) |
| PL (1) | PL329871A1 (enExample) |
| SK (1) | SK150298A3 (enExample) |
| TR (1) | TR199802227T2 (enExample) |
| WO (1) | WO1997042329A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9708910A (pt) * | 1996-05-04 | 1999-08-03 | Zeneca Ltd | Anticorpo conjugado sequência de polinucleotídeos vetor célula hospedeira hibridoma composição farmacêutica processos para fabricar um anticorpo ou um conjugado e para tratar um humano ou animal em necessidade deste tratamento |
| AU6000698A (en) * | 1997-02-14 | 1998-09-08 | Zeneca Limited | Proteins |
| GB9709421D0 (en) * | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
| AU752494B2 (en) * | 1998-02-25 | 2002-09-19 | Dow Chemical Company, The | High affinity humanized ANTI-CEA monoclonal antibodies |
| EP1131428A2 (en) * | 1998-11-19 | 2001-09-12 | Incyte Pharmaceuticals, Inc. | Immunoglobulin superfamily proteins |
| WO2000037615A1 (en) * | 1998-12-21 | 2000-06-29 | Eli Lilly And Company | Recombinant synthesis of beta-lipotropin and other peptides |
| GB2371803A (en) * | 1999-11-18 | 2002-08-07 | Oxford Biomedica Ltd | Antibodies |
| JP2003515323A (ja) * | 1999-11-18 | 2003-05-07 | オックスフォード バイオメディカ（ユーケイ）リミテッド | 抗 体 |
| ES2292587T3 (es) * | 2000-04-22 | 2008-03-16 | Pharmedartis Gmbh | Agentes apoptoticos. |
| GB0210783D0 (en) * | 2002-05-10 | 2002-06-19 | Polonelli Luciano | Anti-microbial polypeptides |
| KR100604037B1 (ko) * | 2002-08-02 | 2006-07-24 | 주식회사유한양행 | 항체 경쇄 카파 발현벡터 |
| US20050008618A1 (en) * | 2003-02-27 | 2005-01-13 | Howard Kaufman | Composition for delivering an agent to a target cell and uses thereof |
| US20070009957A1 (en) * | 2003-03-04 | 2007-01-11 | Alexion Pharmaceuticals, Inc. | Vectors used to create hybrid constant regions |
| NZ542988A (en) * | 2003-04-23 | 2008-07-31 | Medarex Inc | Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies |
| EP1691763A4 (en) * | 2003-12-12 | 2008-03-12 | Genencor Int | MOLECULES CAB |
| CA2556027C (en) * | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| US8088609B2 (en) * | 2004-04-15 | 2012-01-03 | Danisco Us Inc. | CAB molecules |
| CN101072578A (zh) | 2004-10-29 | 2007-11-14 | 南加州大学 | 用共刺激分子的联合癌症免疫疗法 |
| EP2322560B1 (en) | 2005-03-10 | 2013-09-04 | Morphotek, Inc. | Anti-mesothelin antibodies |
| EP2172487A1 (en) | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
| KR101363777B1 (ko) | 2005-09-30 | 2014-02-14 | 메디뮨 리미티드 | 인터루킨―１３ 항체 조성물 |
| EP2046375B1 (en) | 2006-07-20 | 2017-04-05 | The General Hospital Corporation | Methods and compositions for the selective activation of protoxins through combinatorial targeting |
| US8043830B2 (en) * | 2008-02-01 | 2011-10-25 | The Regents Of The University Of California | Biotin-ligase system for secretion of biotinylated protein |
| CN101607985B (zh) * | 2008-12-24 | 2013-03-27 | 中国科学院生物物理研究所 | 抗人cea的单克隆抗体，包含其的组合物，及其用途 |
| CN101704892B (zh) * | 2009-12-09 | 2014-02-12 | 中国人民解放军军事医学科学院生物工程研究所 | 一种抗uPAR人源化抗体及其编码基因与应用 |
| CA2787070A1 (en) * | 2010-01-28 | 2011-08-04 | Ian Kirby | Cd127 binding proteins |
| JP6400470B2 (ja) | 2011-05-16 | 2018-10-03 | ジェネロン（シャンハイ）コーポレイション リミテッド | 多重特異性Ｆａｂ融合タンパク質および使用法 |
| CN104203982B (zh) | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
| CN102526707B (zh) * | 2012-01-13 | 2015-04-22 | 成都博发生物技术有限公司 | 共刺激因子及融合蛋白的新用途 |
| RU2493166C1 (ru) * | 2012-04-09 | 2013-09-20 | Общество с ограниченной ответственностью "Технофарма" | Наноантитело, специфически связывающее белок сеа, способ его использования для детекции этого белка |
| CN102838676A (zh) * | 2012-09-26 | 2012-12-26 | 李彬 | 一种癌胚抗原单抗及包含该抗体的芯片以及应用 |
| DK2839860T3 (da) | 2012-10-12 | 2019-06-17 | Medimmune Ltd | Pyrrolobenzodiazepiner og konjugater deraf |
| ES2687439T3 (es) | 2013-03-13 | 2018-10-25 | Medimmune Limited | Pirrolobenzodiazepinas y conjugados de las mismas |
| US9963515B2 (en) | 2013-04-29 | 2018-05-08 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| PE20170908A1 (es) | 2014-10-29 | 2017-07-12 | Teva Pharmaceuticals Australia Pty Ltd | VARIANTES DE INTERFERON a2b |
| WO2017157305A1 (en) | 2016-03-15 | 2017-09-21 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
| JP7241677B2 (ja) | 2016-07-19 | 2023-03-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗ｃｄ４７併用療法 |
| CN109862919A (zh) | 2016-10-11 | 2019-06-07 | 免疫医疗有限公司 | 抗体-药物缀合物联合免疫介导的治疗剂 |
| CN111533805B (zh) * | 2016-12-04 | 2022-02-08 | 深圳市国创纳米抗体技术有限公司 | 一种抗癌胚抗原的高亲和力纳米抗体及其应用 |
| CA3098103A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| EP3847196A4 (en) | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| WO2020132810A1 (en) | 2018-12-24 | 2020-07-02 | Generon (Shanghai) Corporation Ltd. | Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof |
| US20210128617A1 (en) * | 2019-08-27 | 2021-05-06 | The Trustees Of The University Of Pennsylvania | SYNTHETIC CARS TO TREAT IL13R-alpha-2 POSITIVE HUMAN AND CANINE TUMORS |
| US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
| CN115850483B (zh) * | 2020-10-21 | 2025-09-19 | 北京纽安博生物技术有限公司 | 抗CEACAM6单域抗体、人源化单域抗体及其Fc融合蛋白和应用 |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| CN117980327A (zh) | 2021-11-03 | 2024-05-03 | 杭州多禧生物科技有限公司 | 抗体的特异性偶联 |
| WO2026143022A1 (en) | 2024-12-23 | 2026-07-02 | Point Loma Nazarene University | Antibody directed enzyme pro-drug therapy (adept) for cancer treatment using an antibody or fragment that binds to a cd206 receptor and 3-cyclopentyl-alpha-phenylalanine-methotrexate |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8809616D0 (en) * | 1988-04-22 | 1988-05-25 | Cancer Res Campaign Tech | Further improvements relating to drug delivery systems |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| AU6819494A (en) * | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9324807D0 (en) * | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| BR9708910A (pt) * | 1996-05-04 | 1999-08-03 | Zeneca Ltd | Anticorpo conjugado sequência de polinucleotídeos vetor célula hospedeira hibridoma composição farmacêutica processos para fabricar um anticorpo ou um conjugado e para tratar um humano ou animal em necessidade deste tratamento |
-
1997
- 1997-04-29 BR BR9708910A patent/BR9708910A/pt not_active Application Discontinuation
- 1997-04-29 HU HU9901562A patent/HUP9901562A3/hu unknown
- 1997-04-29 PL PL97329871A patent/PL329871A1/xx unknown
- 1997-04-29 CZ CZ983536A patent/CZ353698A3/cs unknown
- 1997-04-29 CA CA002250579A patent/CA2250579A1/en not_active Abandoned
- 1997-04-29 DE DE69737188T patent/DE69737188T2/de not_active Expired - Fee Related
- 1997-04-29 IL IL12677297A patent/IL126772A0/xx unknown
- 1997-04-29 WO PCT/GB1997/001165 patent/WO1997042329A1/en not_active Ceased
- 1997-04-29 AT AT97918258T patent/ATE350478T1/de not_active IP Right Cessation
- 1997-04-29 NZ NZ331978A patent/NZ331978A/xx unknown
- 1997-04-29 SK SK1502-98A patent/SK150298A3/sk unknown
- 1997-04-29 JP JP09539625A patent/JP2000510692A/ja active Pending
- 1997-04-29 US US09/171,945 patent/US6277599B1/en not_active Expired - Fee Related
- 1997-04-29 TR TR1998/02227T patent/TR199802227T2/xx unknown
- 1997-04-29 ES ES97918258T patent/ES2279539T3/es not_active Expired - Lifetime
- 1997-04-29 AU AU26455/97A patent/AU719513B2/en not_active Ceased
- 1997-04-29 CN CN97194390A patent/CN1217750A/zh active Pending
- 1997-04-29 EP EP97918258A patent/EP0896626B1/en not_active Expired - Lifetime
-
1998
- 1998-11-03 NO NO985120A patent/NO985120L/no not_active Application Discontinuation
-
2001
- 2001-07-23 US US09/910,059 patent/US6903203B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1217750A (zh) | 1999-05-26 |
| AU2645597A (en) | 1997-11-26 |
| EP0896626B1 (en) | 2007-01-03 |
| US6903203B2 (en) | 2005-06-07 |
| PL329871A1 (en) | 1999-04-12 |
| DE69737188D1 (de) | 2007-02-15 |
| HUP9901562A3 (en) | 2000-06-28 |
| NO985120L (no) | 1998-12-29 |
| WO1997042329A1 (en) | 1997-11-13 |
| AU719513B2 (en) | 2000-05-11 |
| ES2279539T3 (es) | 2007-08-16 |
| BR9708910A (pt) | 1999-08-03 |
| HUP9901562A2 (hu) | 1999-08-30 |
| DE69737188T2 (de) | 2007-10-11 |
| US6277599B1 (en) | 2001-08-21 |
| CZ353698A3 (cs) | 1999-02-17 |
| SK150298A3 (en) | 1999-04-13 |
| IL126772A0 (en) | 1999-08-17 |
| NO985120D0 (no) | 1998-11-03 |
| US20020142359A1 (en) | 2002-10-03 |
| TR199802227T2 (xx) | 2000-07-21 |
| ATE350478T1 (de) | 2007-01-15 |
| JP2000510692A (ja) | 2000-08-22 |
| CA2250579A1 (en) | 1997-11-13 |
| EP0896626A1 (en) | 1999-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL126772A0 (en) | Monoclonal antibody of cea conjugates comprising said antibody and their therapeutic use in an adept system | |
| CA2250080A1 (en) | Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications | |
| AU6356986A (en) | Ma6 anti human breast cancer for imaging process | |
| AU2739188A (en) | Novel antibodies | |
| WO1997044461A3 (en) | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers | |
| KR920700692A (ko) | 사람의 종양과 연합한 신규 항원에 대한 신규의 일클론 항체 | |
| KR910700077A (ko) | 인체 종양과 관련된 신규 항원에 대한 신규한 모노클로날 항체 | |
| YU45501A (sh) | Humana monoklonalna antitela za ctla-4 | |
| RU2012102323A (ru) | Способ лечения ревматоидного артрита посредством лекарственного препарата на основе выделенного человеческого антитела или его антигенсвязывающего фрагмента | |
| NZ508381A (en) | Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5) | |
| GB2236529B (en) | Cross-linked antibodies and processes for their preparation | |
| LU91375I2 (fr) | Abatacept et ses dérivés pharmaceutiquement acceptables (ORENCIA R) | |
| CA2065325A1 (en) | Cdr grafted anti-cea antibodies and their production | |
| USRE38008E1 (en) | Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof | |
| ATE173740T1 (de) | Antikoerper mit geaenderter zielrichtung | |
| WO1996021734A3 (en) | P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods | |
| AU2709295A (en) | Human monoclonal antibodies specific to cell cycle independent glioma surface antigen | |
| AU641736B2 (en) | Delivery of agents | |
| IE880976L (en) | Human tumour-associated antigen | |
| Gold et al. | Murine monoclonal antibodies to colon-specific antigen p | |
| Ditzel et al. | Tumour localization and pharmacokinetics of iodine-125 human monoclonal IgM antibody (COU-1) and its monomeric and half-monomeric fragments analysed in nude mice grafted with human tumour | |
| DE69031225D1 (de) | Monoklonaler antikörper zur differenzierung von "squamous cell carcinoma"-antigenen und verfahren zu dessen verwendung | |
| Oltrogge et al. | How to overcome the disturbing effects of human anti-mouse antibodies (HAMA) on in vitro assays | |
| CA2219961A1 (en) | Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof | |
| CA2255540A1 (en) | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |